Similar articles

• Virology. Moving forward in HIV vaccine development.

  Letvin NL. Letvin NL. Science. 2009 Nov 27;326(5957):1196-8. doi: 10.1126/science.1183278. Science. 2009. PMID: 19965456 No abstract available.
• HIV vaccines. Viral envelope fails to deliver?

  Bolognesi DP, Matthews TJ. Bolognesi DP, et al. Nature. 1998 Feb 12;391(6668):638-9. doi: 10.1038/35504. Nature. 1998. PMID: 9490406 No abstract available.
• Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

  Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group. Pitisuttithum P, et al. J Infect Dis. 2006 Dec 15;194(12):1661-71. doi: 10.1086/508748. Epub 2006 Nov 3. J Infect Dis. 2006. PMID: 17109337 Clinical Trial.
• Development of prophylactic AIDS vaccines: the current state of affairs.

  Hanke T. Hanke T. Curr Opin Mol Ther. 2003 Feb;5(1):25-32. Curr Opin Mol Ther. 2003. PMID: 12669467 Review.
• HIV-1/AIDS vaccine development: are we in the darkness.

  Qiu C, Xu JQ. Qiu C, et al. Chin Med J (Engl). 2008 May 20;121(10):939-45. Chin Med J (Engl). 2008. PMID: 18706210 Review. No abstract available.